Literature DB >> 16035397

Symptomatic treatment of osteoarthritis: paracetamol or NSAIDs?

Karel Pavelka1.   

Abstract

The clinical management of osteoarthritis (OA) is today symptomatic, its main goals being relief of pain and improvement of function. Therapy should be multimodal and composed of non-pharmacological, pharmacological and, if necessary, surgical procedures. Paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) are evidence-based drugs for the symptomatic relief of OA. Newly published comparative studies have shown that NSAIDs are more effective than paracetamol--in contrast to studies from the early 1990s. Some studies have documented that more severe pain and the presence of inflammation can predict better response from NSAIDs than from paracetamol; on the other hand other studies have not confirmed this. Patient preference studies have shown that patients favour NSAIDs, but up to 40% consider paracetamol at least as effective as NSAIDs. With regard to efficacy, safety and cost, the majority of new guidelines recommend paracetamol as a first-choice analgesic for patients with OA of the knee or hip, and the use of NSAIDs only in cases of inadequate effect of paracetamol and especially in the presence of inflammation. There is much evidence that OA is a phasic disease and it may be that NSAIDs are useful during identifiable periods of inflammatory activity and can be avoided at other times. The concept of the short-term use of NSAIDs during flares and the use of a simple analgesic in the long term seems to be the best variant for the majority of patients with optimal benefit/risk and cost-effectiveness.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16035397     DOI: 10.1111/j.1742-1241.2004.005_b.x

Source DB:  PubMed          Journal:  Int J Clin Pract Suppl        ISSN: 1368-504X


  6 in total

1.  How Do Physical Therapists Treat People with Knee Osteoarthritis, and What Drives Their Clinical Decisions? A Population-Based Cross-Sectional Survey.

Authors:  Bruno R da Costa; Edgar Ramos Vieira; Inae Caroline Gadotti; Conner Colosi; James Rylak; Travis Wylie; Susan Armijo-Olivo
Journal:  Physiother Can       Date:  2017       Impact factor: 1.037

Review 2.  Applying the evidence in osteoarthritis: strategies for pain management.

Authors:  Edward C Huskisson
Journal:  Clin Drug Investig       Date:  2007-12       Impact factor: 2.859

3.  Treatment satisfaction after switching to another therapy in Spanish orthopaedic clinic outpatients with knee or hip osteoarthritis previously refractory to paracetamol.

Authors:  Angel Oteo-Álvaro; María T Marín; Miguel A Ruiz-Ibán; Beatriz Armada; Javier Rejas
Journal:  Clin Drug Investig       Date:  2012-10-01       Impact factor: 2.859

4.  Bone resorption and remodeling in murine collagenase-induced osteoarthritis after administration of glucosamine.

Authors:  Nina Ivanovska; Petya Dimitrova
Journal:  Arthritis Res Ther       Date:  2011-03-16       Impact factor: 5.156

5.  Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta.

Authors:  Jean-Noël Gouze; Elvire Gouze; Mick P Popp; Marsha L Bush; Emil A Dacanay; Jesse D Kay; Padraic P Levings; Kunal R Patel; Jeet-Paul S Saran; Rachael S Watson; Steven C Ghivizzani
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

6.  Design, synthesis, biological assessment and in silico ADME prediction of new 2-(4-(methylsulfonyl) phenyl) benzimidazoles as selective cyclooxygenase-2 inhibitors.

Authors:  Mohamed A S Badawy; Eman K A Abdelall; El-Shaymaa El-Nahass; Khaled R A Abdellatif; Hamdy M Abdel-Rahman
Journal:  RSC Adv       Date:  2021-08-17       Impact factor: 4.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.